title: TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL.
authors.forename: E
authors.initials: E
authors.lastname: Fronkova
authors.forename: J
authors.initials: J
authors.lastname: Madzo
authors.forename: J
authors.initials: J
authors.lastname: Zuna
authors.forename: L
authors.initials: L
authors.lastname: Reznickova
authors.forename: K
authors.initials: K
authors.lastname: Muzikova
authors.forename: O
authors.initials: O
authors.lastname: Hrusak
authors.forename: J
authors.initials: J
authors.lastname: Stary
authors.forename: J
authors.initials: J
authors.lastname: Trka
mesh_terms: D002648:Child; D050676:Core Binding Factor Alpha 2 Subunit; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis*; D011446:Prospective Studies; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D007136:Immunoglobulins; D015514:Oncogene Proteins, Fusion; D011948:Receptors, Antigen, T-Cell; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein